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Abstract
FBXO7 is implicated in the ubiquitin–proteasome system and parkin-mediated
mitophagy. FBXO7defects cause a levodopa-responsive parkinsonian-pyramidal
syndrome(PPS). Methods: We investigated the disease molecular bases in a
child with PPS and brain iron accumulation. Results: A novel homozygous
c.368C>G (p.S123*) FBXO7 mutation was identified in a child with spastic
paraplegia, epilepsy, cerebellar degeneration, levodopa nonresponsive parkinson-
ism, and brain iron deposition. Patient’s fibroblasts assays demonstrated an
absence of FBXO7 RNA expression leading to impaired proteasome degradation
and accumulation of poly-ubiquitinated proteins. Conclusion: This novel
FBXO7 phenotype associated with impaired proteasome activity overlaps with
neurodegeneration with brain iron accumulation disorders.
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Introduction
Parkinsonism-pyramidal syndrome (PPS) is a complex
movement disorder that may present in childhood associ-
ated with complex hereditary spastic paraplegia (SPG),
young-onset parkinsonism, neurodegeneration with brain
iron accumulation (NBIA) disorders, and inborn errors of
metabolism.1 FBXO7 deficiency (PARK15; MIM 260300) is
a rare cause of PPS with 26 known patients since 2008.2-9
Most of these patients develop spastic paraparesia and/or
levodopa-responsive young onset parkinsonism with nor-
mal brain magnetic resonance imaging (MRI) and reduced
dopamine uptake on DaTSCAN.2-9 The F-box only pro-
tein7 (FBXO7) gene encodes for a protein involved in
ubiquitin–proteasome system (UPS) activity and mito-
phagy. FBXO7 protein is a subunit of a complex responsi-
ble for the phosphorylation-dependent ubiquitination, the
SKP1/cullin-1/F-box protein (SCF) E3 ubiquitin ligase
complex. FBXO7 acts as a substrate recruiter in this com-
plex and has a regulatory role in proteasome through the
direct interaction with the core proteasome subunit
PSMA2, an essential protein required for a fully functional
proteasome. Another role of FBXO7 protein is to provide
an effective recruitment of parkin to damaged mitochon-
dria and initiate mitophagy.10-13
The genetic analysis of a child with a complex pheno-
type including epilepsy, progressive PPS with no response
to levodopa, cognitive decline, and MRI features sugges-
tive of NBIA revealed the novel homozygous FBXO7
c.368C>G (p.S123*) variant. We detected for the first
time in patient’s fibroblasts an impairment in ubiquitin-
protein degradation and poly-ubiquitinated (poly-UB)
proteins accumulation, (highlighting the essential role of
the UPS activity of FBXO7 in human disease.
Methods
Used methodology is summarized in the main manu-
script. Complete procedures and protocols are detailed in
Supporting Information.
Consent and approval
All protocols complied with the ethics guidelines accord-
ing to the Declaration of Helsinki and were approved by
participating institutional review boards. The proband
and relatives signed an informed consent for the study.
Genetic studies
Genetic test was performed in the proband using a cus-
tomized gene panel. Because of second-grade parental
consanguinity, homozygous variants were prioritized.
Cell culture and western-blot
Skin cultured fibroblasts from the patient and controls
were grown in standard medium. FBXO7 expression and
mitophagy-related proteins (PINK1, Parkin, K63 poly-UB,
VDAC1) were studied by Western blot in homogenate
and mitochondrial enriched fractions.
Nonsense-mediated mRNA decay (NMD)
assay
Proband and control fibroblasts cultures were treated with
emetine dihydrochloride hydrate,14 a specific inhibitor of
translation. RNA was extracted and retro-transcribed, and
the resulting cDNAs underwent qPCR for the quantifica-
tion of FBXO7 RNA expression.
Ubiquitin–proteasome system activity and
expression assays
Chymotrypsin-like activity determination was done mea-
suring fluorescence intensity after incubation of the pro-
band and control fibroblasts’ protein extract with a
proteasome activity buffer and a fluorogenic substrate.
Ubiquitinated-protein levels were quantified through a
WB assay using an anti-UB antibody (Sigma-Aldrich, St.
Louis, USA).
Electronic microscopy
Ultra-thin sections were examined under a transmission
electron microscope FEI Tecnai Spirit BioTwin using a
digital camera Morada (see Supplemental File).
Results
Case Presentation
The proband is currently a 21-year-old girl born to
healthy consanguineous parents from Morocco. After a
normal perinatal history, she presented with mild
global developmental delay followed by acute ataxia
triggered by a viral gastroenteritis at 2 years. When she
was 5 years old, valproate was started for absence epi-
lepsy. She was lost to follow-up until the age of 12,
when she was admitted to the intensive care unit due
to acute parainfectious H1N1 encephalopathy. Neuro-
logical examination identified horizontal nystagmus,
head tremor, dysmetria, lower limb spasticity, hyper-
reflexia, clonus, bilateral Babinski sign, and bladder dys-
function.
Between the age of 12 and 18 years the patient suffered
progressive deterioration, including progressive spastic
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paraparesia and gait loss at 13 years, language and cogni-
tive regression, drug-resistant seizures, severe dysphagia,
and optic neuropathy. At the age of 15, hypokinesia,
rigidity, kinetic tremor, and upgaze limitation were iden-
tified. A trial with levodopa (100g/day) did not show a
positive response (Video).
Serial brain and medulla MRI studies from 10 to
17 years disclosed slight vermian atrophy progressing to
cerebral and cerebellar atrophy, and a hot cross bun
sign suggesting ponto-cerebellar tract degeneration.
Excessive brain iron deposition in the pallidum and
substantia nigra appeared as hypointense signal on iron-
sensitive sequences at 15 years, which led us to suspect
a causative relation with the onset of parkinsonian fea-
tures (Fig. 1). At 20 years, a brain DaTSCAN showed
normal uptake.
Genetic findings
Data analysis of a custom gene panel identified two
homozygous variants: c.100A>G (p.T34A) in DLD
(NM_000108.4) and c.368C>G (p.S123*) in FBXO7
(NM_012179.3) (Fig. 2A). In parallel, exome sequencing
analysis revealed the same findings (data not shown). In
Figure 1. MRI proband’s studies: T1WI sagittal images (A) at 10 years old (B), 12 years old (C), 15 years old and (D) 17 years old show a
progression from slight vermian atrophy to cerebellar atrophy of vermis and hemispheres, cerebral volume loss and brainstem atrophy, enlarged
ventricles, and cerebral sulci at the age of 17. Axial T2WI of the pons at (E) 12 years old, (F) 15 years old and (G) 17 years old. T2 hyperintensity
delineating a cross through the pons known as the “hot cross bun” sign and representing selective degeneration of pontocerebellar tracts appear
at the age of 17. Gradient recall echo [GRE] sequence basal ganglia at (H) 12 years old (I), 15 years old and (J) and 17 years. Bilateral
hypointensities in pallidum suggest that iron deposition appeared at 15 years.
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silico predictors showed that DLD p.T34A (rs138002793;
MAF = 5.1 9 10-4) was probably benign. DLD enzyme
activity assay in patient’s fibroblasts was considered
within the normal range of activity. According to these
findings and the patient’s clinical record, we ruled out the
implication of DLD. Although gene panel data analysis
disclosed a moderate number of single-exon CNVs in the
proband, array-CGH found no pathological results (data
not shown).
Functional studies
The novel FBXO7 c.368C>G (p.S123*) change would pro-
duce a very short protein where the only functional
domain preserved would be the ubiquitin-like domain
(Fig. 2B). Protein expression analysis showed the absence
of FBXO7 protein in WB (Fig. 2C). mRNA expression
was investigated by NMD assay confirming a significant
decrease in FBXO7 mRNA in patient’s fibroblasts
compared to control (P < 0.05). Emetine incubation
increased total mRNA in patient’s fibroblasts up to con-
trol levels, thus confirming a NMD mechanism as a cause
of loss of function effect (Fig. 2D).
Loss of FBXO7 is related to decreased proteasome
activity.10 A significant reduction of 20% in UPS activity
was observed in patient’s fibroblasts (Fig. 2E). We
hypothesized that impaired UPS would not be able to
degrade the poly-UB labeled proteins and we found an
increase in these proteins in proband’s fibroblasts
(Fig. 2F).
FBOX7 is also involved in mitophagy.12,13 Mitophagy-
related proteins studies showed no significant differences
in mitochondrial enriched fractions in patient’s fibroblasts
(Fig. S1A). However, elevated mitochondrial proteins in
mutant cells were observed, possibly due to accumulated
mitochondria (Fig. S1B). Mitochondria analysis by elec-
tron microscopy revealed abnormal cristae morphology in
ultra-thin sections images (Fig. S1C).
Figure 2. Pedigree and analysis of the FBXO7 p.S123* mutation: (A) FBXO7 c.368C>G (p.S123*) mutation family’s pedigree. The index case (II:1)
is homozygous for the mutation (black circle with an arrow). Her healthy relatives are heterozygous carriers (half-shaded symbols). (B) Distribution
of pathogenic mutations reported in FBXO7 according to protein domains; p.S123* (in bold) is located in an inter-domain between the UBL and
the CDK6 domains. (C) Absence of FBXO7 protein western blot in patient’s fibroblasts (II:1) compared to two controls fibroblasts’ lysates (C1 and
C2) immunodetected with an antibody against FBXO7. (D) mRNA expression was evaluated by qPCR in fibroblasts from the patient (II:1) and one
control with and without emetine treatment, a translation inhibitor. FBXO7 mRNA levels in patient’s fibroblasts (II:1) are rescued when treated
with emetine. Data were obtained from one biological sample and three independent technical replicates. Error bars represent SEM. Mann–
Whitney–Wilcoxon test: *P < 0.05; n.s: nonsignificant. (E) UPS activity assay performed in fibroblasts from the patient (II:1) and one control (C3)
shows a reduction of 20% UPS activity in patient. Data were obtained from one biological sample and six independent technical replicates. Error
bars represent SEM. Mann–Whitney–Wilcoxon test: *P < 0.05. (F) Detection of a trend to increase in poly-UB proteins in patient (II:1) fibroblasts
by Western blot and SDS-PAGE. Actin was used to validate equal protein loading. Data were obtained from one biological sample
and three independent technical replicates. Error bars represent SEM. Mann–Whitney–Wilcoxon test. n.s: nonsignificant
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Discussion
FBXO7 deficiency is a rare genetic condition described in
26 patients from 10 unrelated families, giving three major
phenotypes: autosomal recessive juvenile-onset levodopa
responsive PPS (14 patients), SPG (7 patients), and iso-
lated parkinsonism (5 patients).2-9 We report a patient
with a novel, complex, and severe form of childhood
onset FBXO7-PPS with initial developmental delay and
progressive SPG, drug-resistant epilepsy, levodopa nonre-
sponsive parkinsonism, and signs of cerebellar degenera-
tion and basal ganglia iron deposition.
We observed a striking association between the onset of
parkinsonian features and the occurrence of brain iron
accumulation on MRI at 15 years. These findings, together
with poor levodopa response and normal dopamine uptake
suggested a likely postsynaptic degeneration condition
overlapping with NBIA disorders. This contrasts previous
reports showing a severe nigrostriatal dopaminergic defect
in two patients carrying FBXO7 mutations.3,4
Moreover, the patient suffered from cerebellar ataxia,
oculomotor dysfunction, severe dysphagia, and cognitive
decline. These features could be related to the progression
of cerebellar atrophy and the appearance of a hot cross
bun sign at the pons, also described in patients with mul-
tiple system atrophy or spinocerebellar ataxia.15 Neither
brain iron accumulation nor the hot cross bun sign have
been reported in FBXO7 patients, mostly having normal
structure or mild global brain atrophy on MRI
(Table S1).
Previous FBXO7 patients with nonsense variants had
the onset of core features within the second decade of life,
and progression to severe parkinsonism, major disability
or early death in five of 13 cases.3-6,8,9 However, none of
them developed epilepsy or cerebellar ataxia, two atypical
features of our patient. On the other hand, patients with
missense variants showed milder phenotypes, such as
young onset parkinsonism or isolated SPG, probably due
to a possible residual activity of FBXO77 (Table. S1).
The FBXO7 c.368C>G (p.S123*) nonsense mutation is
located in the proximal region of the protein. According
to our results, it would produce an aberrant mRNA,
which was degraded by NMD, leading to a complete
absence of FBXO7 protein and a loss of function effect.
NMD is a well-known RNA quality control that limits the
expression of mRNAs with premature termination
codons.16,17 Previously, two additional nonsense FBXO7
mutations (p.R498* and p.E470*) were reported.3,9 The
absence of expression of p.R498* was demonstrated in a
human cell model, however, NMD process was discarded
probably due to its location near the C-ter.18
FBXO7 plays a regulatory role in proteasome and mito-
chondria. The FBXO7 knockdown in mice results in a
decrease in UPS activity.10 We have demonstrated that
the UPS activity was reduced in FBXO7-PPS patient’s
fibroblasts, and as a consequence, the poly-UB proteins
showed a trend to accumulate. Moreover, our findings
suggest a likely mechanistic relationship between protea-
some impairment and iron accumulation, previously
observed in experimental models of PD. A mice model of
PD induced by the proteasome inhibitor lactacystin
showed loss of dopamine neurons, abnormal iron accu-
mulation, and elevated iron regulatory protein 2 (IRP2)
and divalent metal transporter 1 (DMT1) in the substan-
tia nigra.19 Also, the in vitro lactacystin dopamine cell
line model showed an increase in labile iron, disruption
in iron regulatory proteins, and aggregation of ubiquitin-
conjugated proteins, leading to cell premature death.20
Taken together, these findings suggest that alterations in
iron regulatory proteins due to proteasome dysfunction
may lead to dopamine neuron degeneration.
In addition, PINK1/Parkin-mediated mitophagy is facil-
itated by FBXO7 and dependent on ubiquitin.11,13,21-23
We have not found differences in the expression of mito-
phagy-related proteins between mutant and healthy
fibroblasts. However, elevated mitochondrial proteins in
mutant cells were observed, possibly due to accumulated
mitochondria.
Mitochondrial cristae alterations are associated with
mitochondria impairment.24 In a transgenic Drosophila
model, the overexpression of FBXO7 leads to broken cris-
tae and accumulated high-density material in the swollen
mitochondria.11 We observed abnormal mitochondrial
cristae morphology in patient’s fibroblasts, likely as a sec-
ondary consequence, since it is commonly seen in neu-
rodegenerative diseases, including NBIA forms.25-27
Our results have major limitations and should be inter-
preted with caution as they have been demonstrated in a
single patient harbouring FBXO7 p.S123* mutation. Fur-
ther studies are needed to clarify if proteosome impair-
ment, mitophagy dysfunction, and iron accumulation are
the main biological mechanisms leading to PPS in FBXO7
patients.
In conclusion, we describe a complex and severe
FBXO7-related phenotype with a likely postsynaptic
mechanism of neurodegeneration, which overlaps with
other NBIA monogenic diseases. The absence of FBXO7
led to impaired proteasome degradation and accumula-
tion of poly-ubiquitinated proteins, which highlights the
essential role of the UPS in the disease mechanism.
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Video Segment A. The patient at 13 years old is in a
wheelchair due to spastic paraplegia.
Video Segment B. The patient at 15 years old has severe
hypomimia, bradykinesia, and low amplitude kinetic tre-
mor while throwing the ball.
Video Segment C. Oculomotor features of patient at
16 years old are horizontal nystagmus and reduced
upgaze during smooth pursuit.
Video Segment D. Neurologic assessment at 21 years old
reveals lower limbs hyperreflexia, bilateral Babinski sign,
and Achilles clonus. On a second frame, we also observe
upper limb bradykinesia, action tremor, and myoclonus.
File S1. Additional information regarding materials and
methods, a supplementary figure and a supplementary
table are included in a supplementary material file.
Figure S1. Mitophagy-related proteins and electron
microscopy: (A) Mitophagy markers (PINK1, Parkin,
K63-polyUb, and VDAC) levels analyzed by Western-blot
in mitochondria enriched fractions from patient’s and
control’s fibroblasts. Error bars represent SEM. n.s.: non-
significant. (B) Elevated levels of mitochondrial-specific
proteins PINK1 and VDAC1 were detected in mutant
cells compared to controls. Error bars represent SEM.
Mann–Whitney–Wilcoxon test: *P < 0.05; n.s.: nonsignif-
icant. (C) Analysis of mitochondrial morphology by elec-
tron microscopy revealed in ultrathin sections images of
mitochondria in control’s and patient’s fibroblasts. Inter-
nal scales marker are indicated in the figure.
Table S1. Genetic, clinical, and neuroimaging features of
FBXO7 deficiency
Supplementary Material
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